CCRM Nordic and GoCo announces the construction of GoCo Active Lab
Date:
25 January 2024Place:
Gothenburg
In May 2023, Sweden's innovation agency Vinnova in collaboration with an industry consortium, committed to a substantial investment of 160 million SEK in the innovation platform at GoCo Health Innovation City, located in Mölndal outside Gothenburg. This strategic decision aimed to propel Sweden into a world-leading position in life science.
Just eight months later, construction is now starting on GoCo Active Lab, where research into new drugs and therapies will be combined with a unique approach to accelerate development in preventive healthcare. This is celebrated with a major event on January 25th together with the most interesting actors in health.
CCRM Nordic’s purpose-built laboratory in GoCo Active lab will feature 2000 m2 of GMP manufacturing clean rooms and laboratories, along with 1000 m2 dedicated to process development.
“We are very proud and pleased that we get to move into a building that meets our needs for advanced labs and at the same time provides us with an opportunity for collaboration, innovation and focus on people’s health. This is completely in line with what we stand for and gives us the right conditions for successfully contributing to the development of future drugs”, says Fredrik Wessberg, CEO of CCRM Nordic.
Read More
News – GoCo Health Innovation City
About CCRM Nordic:
CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.
About CCRM:
CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca